Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

Study Design

Population
human monocyte-derived macrophages and dendritic cells, and MRC-5 fibroblasts
Methods
We investigated the effect of Bifidobacterium lactis Bl-04 on cytokine production and transcriptomes of human monocyte-derived macrophages and dendritic cells, and further on RV replication and cytokine production in MRC-5 fibroblasts.
Consumption of certain probiotic strains may be beneficial for reducing the risk of acute upper respiratory tract infections (URTIs), however, underlying immunological mechanisms are elusive. Bifidobacterium lactis Bl-04™ has been reported in humans to significantly reduce the risk of URTIs, affect the innate immunity in the nasal mucosa, and reduce nasal lavage virus titer after a rhinovirus (RV) challenge. To study the immunological mechanisms, we investigated the effect of Bl-04 on cytokine production and transcriptomes of human monocyte-derived macrophages (Mfs) and dendritic cells (DCs), and further on RV replication and cytokine production in MRC-5 fibroblasts. The results showed that Bl-04 modulates antiviral immune responses and potentiates cytokine production during viral challenge mimic in immune cells. However, effect of Bl-04 on RV replication and cytokine production in fibroblasts was negligible. Overall, the findings suggest that Bl-04 mildly stimulates antiviral immunity in Mfs and DCs, and potentially influences viral replication in fibroblasts that however warrants further investigations.

Research Insights

SupplementDoseHealth OutcomeEffect TypeEffect SizeSource
Bifidobacterium lactisEnhanced Innate Antiviral Immune ResponseBeneficial
Small
View source

Bl-04 mildly stimulates antiviral immunity in Mfs and DCs

Bifidobacterium lactisReduced Rhinovirus Nasal Lavage TiterBeneficial
Small
View source

reduce nasal lavage virus titer after a rhinovirus (RV) challenge

Bifidobacterium lactisReduced Risk of Upper Respiratory Tract InfectionsBeneficial
Moderate
View source

Bifidobacterium lactis Bl-04™ has been reported in humans to significantly reduce the risk of URTIs

Back to top